Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04083976 · ClinicalTrials.gov registry record · Phase 2

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

A Phase 2 study of Advanced Solid Tumor, sponsored by Janssen Research & Development.

Active
Registry status
Phase 2
Development phase
316
Enrollment target
20
Study locations

NCT04083976 is a Phase 2 study of Advanced Solid Tumor that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 316 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04083976, a Phase 2 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
316 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Erdafitinib

Study Locations (20)

Florida

  • Memorial Cancer Institute - Hollywood
  • Cancer Specialists of North Florida - Jacksonville

New York

  • Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • Oncology Hematology Care - Cincinnati
  • Nationwide Children's Hospital - Columbus

Pennsylvania

  • Thomas Jefferson University - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Tennessee

  • Tennessee Oncology, PLLC - Chattanooga
  • Tennessee Oncology - Nashville

Arizona

  • Arizona Oncology Associates, PC - HOPE - Tucson

Colorado

  • Rocky Mountain Cancer Centers - Colorado Springs

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 316 participants
Start Date 2019-11-20
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04083976

The ClinicalTrials.gov registry entry for NCT04083976 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (65% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Erdafitinib is the first listed.

NCT04083976 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT04083976 about?

NCT04083976 is a clinical study titled "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations". The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric pa...

What is the current status of trial NCT04083976?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2019-11-20. Estimated completion is 2026-12-31.

What conditions does trial NCT04083976 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04083976?

The interventions under investigation include: Erdafitinib (DRUG).

Who is sponsoring clinical trial NCT04083976?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04083976 being conducted?

This trial has 20 study locations across Arizona, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.